PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s stock price fell 6.1% during mid-day trading on Monday . The stock traded as low as $0.7682 and last traded at $0.7736. 580,258 shares traded hands during trading, an increase of 6,471% from the average session volume of 8,831 shares. The stock had previously closed at $0.8236.
PharmaCyte Biotech Stock Performance
The firm’s fifty day moving average price is $0.91 and its 200-day moving average price is $0.98.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Further Reading
- Five stocks we like better than PharmaCyte Biotech
- 3 Stocks to Consider Buying in October
- Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
- Top Biotech Stocks: Exploring Innovation Opportunities
- Congress Beat the Market Again—Here Are the 3 Stocks They Bought
- Stock Analyst Ratings and Canadian Analyst Ratings
- Go on a Shopping Spree With 3 Top Retail ETFs
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
